ovid
therapeutics
provides
soticlestat
results
arcade
endymion
studies
showing
seizure
reduction
rare
epilepsies
results
pilot
phase
arcade
study
endymion
extension
study
deficiency
disorder
cdd
syndrome
show
seizure
frequency
reduction
time
cdd
patients
median
motor
seizure
frequency
reduction
arcade
study
increasing
reduction
endymion
extension
study
clinical
global
impression
change
caregiver
global
impression
change
care
suggest
improvements
beyond
motor
seizure
frequency
reduction
cdd
patients
soticlestat
generally
well
tolerated
studies
continues
demonstrate
favorable
safety
profile
new
york
globe
newswire
ovid
therapeutics
nasdaq
ovid
biopharmaceutical
company
committed
developing
medicines
transform
lives
people
rare
neurological
diseases
today
announced
results
arcade
endymion
studies
soticlestat
patients
developmental
epileptic
encephalopathies
dees
rare
epilepsies
phase
arcade
study
pilot
study
soticlestat
patients
deficiency
disorder
cdd
syndrome
two
highly
refractory
rare
epilepsies
approved
treatment
options
endymion
extension
study
soticlestat
patients
completed
arcade
study
opted
roll
endymion
soticlestat
potent
highly
selective
oral
inhibitor
enzyme
cholesterol
developed
collaboration
takeda
pharmaceutical
company
limited
together
data
arcade
endymion
studies
show
seizure
frequency
reduction
time
cdd
patients
median
motor
seizure
frequency
reduction
maintenance
period
arcade
study
increasing
reduction
endymion
extension
study
five
cdd
patients
reached
nine
months
continuous
treatment
patients
increase
median
motor
seizure
frequency
arcade
study
maintenance
period
however
data
four
patients
reached
nine
months
continuous
treatment
showed
reduction
median
motor
seizure
frequency
soticlestat
generally
well
tolerated
studies
continues
demonstrate
favorable
safety
profile
data
reported
today
consistent
build
upon
previous
findings
soticlestat
cdd
patients
various
seizure
types
multiple
concomitant
antiseizure
medications
per
current
medical
practice
yet
still
lack
significant
control
respective
seizures
said
amit
rakhit
mba
president
chief
medical
officer
ovid
therapeutics
data
arcade
small
study
endymion
support
previous
findings
early
activity
soticlestat
importantly
endymion
study
shows
seizure
frequency
reduction
across
multiple
rare
epilepsies
time
data
arcade
endymion
help
inform
next
development
steps
soticlestat
program
cdd
prepare
discuss
data
phase
elektra
study
dravet
syndrome
syndrome
drugs
lose
efficacy
time
soticlestat
may
produce
acute
antiseizure
effects
addition
potential
improvements
outside
motor
seizure
frequency
reduction
suggested
clinical
global
impression
scales
said
scott
demarest
child
epileptologist
assistant
professor
pediatrics
neurology
university
colorado
soticlestat
emerging
potentially
valuable
therapeutic
option
particularly
given
favorable
safety
profile
potential
provide
durable
treatment
benefit
patients
disorders
need
options
manage
seizures
collective
data
phase
elektra
arcade
endymion
studies
warrant
investigation
arcade
phase
pilot
study
designed
inform
potential
future
development
soticlestat
cdd
study
enrolled
patients
ages
years
refractory
epileptic
seizures
associated
cdd
consisted
screening
period
establish
baseline
seizure
frequency
followed
treatment
period
including
titration
dose
optimization
period
maintenance
period
patients
study
allowed
one
six
concomitant
drugs
aeds
majority
patients
concomitantly
treated
least
four
aeds
representing
highly
refractory
patient
population
primary
objective
arcade
study
determine
percent
change
baseline
motor
seizure
frequency
maintenance
period
afterward
patients
offered
chance
continue
soticlestat
treatment
endymion
extension
study
patients
completed
arcade
elected
roll
endymion
endymion
extension
study
soticlestat
patient
participated
previous
soticlestat
dee
clinical
study
including
patients
cdd
dravet
syndrome
syndrome
primary
objective
endymion
assess
safety
tolerability
soticlestat
patients
dees
secondarily
evaluate
effect
soticlestat
seizure
control
time
data
deficiency
disorder
cdd
cdd
patients
exhibited
variety
seizures
types
including
motor
tonic
atonic
cluster
seizures
well
epileptic
spasms
cdd
patients
median
motor
seizure
frequency
reduction
study
period
dose
titration
maintenance
period
maintenance
period
primary
objective
study
arcade
study
two
cdd
patients
experienced
reduction
motor
seizures
one
cdd
patient
experienced
reduction
motor
seizures
study
period
cdd
patients
rolled
endymion
extension
study
continue
receive
soticlestat
five
cdd
patients
reached
nine
months
continuous
treatment
soticlestat
achieving
median
motor
seizure
frequency
reduction
time
interval
beyond
motor
seizures
individual
cdd
patients
also
demonstrated
improvements
seizure
types
reported
previously
overall
clinical
benefit
treatment
assessed
clinical
global
impression
change
investigator
caregiver
global
impression
change
care
scales
cdd
patients
deemed
markedly
improved
minimal
adverse
events
scale
starting
soticlestat
treatment
scale
caregivers
reported
improvement
soticlestat
treatment
end
arcade
study
reporting
much
much
improved
arcade
study
cdd
cohort
exit
interviews
caregiver
also
give
insight
improvements
verbal
nonverbal
communication
alertness
level
engagement
overall
quality
daily
functioning
domains
suggest
benefits
soticlestat
treatment
domains
beyond
seizure
control
data
syndrome
patients
also
exhibited
variety
seizures
types
including
motor
tonic
atonic
myoclonic
absence
seizures
patients
increase
median
motor
seizure
frequency
study
period
dose
titration
maintenance
period
increase
maintenance
period
primary
objective
study
however
data
four
patients
reached
nine
months
continuous
treatment
soticlestat
endymion
showed
reduction
median
motor
seizure
frequency
individual
patients
demonstrated
improvements
seizure
types
reported
previously
addition
patients
deemed
markedly
improved
minimal
adverse
events
scale
starting
soticlestat
treatment
scale
patients
caregivers
reported
improvement
soticlestat
treatment
end
arcade
study
exit
interviews
caregiver
arcade
study
cohort
also
show
similar
improvements
cdd
patients
study
safety
tolerability
profile
soticlestat
soticlestat
generally
well
tolerated
arcade
study
demonstrated
safety
profile
consistent
findings
previous
studies
new
safety
signals
identified
common
adverse
events
constipation
rash
seizure
additionally
serious
adverse
events
considered
related
study
drug
deaths
reported
initial
arcade
data
results
arcade
patients
enrolled
endymion
continue
demonstrate
safety
profile
consistent
previous
findings
arcade
study
reduction
plasma
levels
observed
soticlestat
treatment
plasma
continues
show
potential
biomarker
pharmacodynamic
activity
detailed
efficacy
safety
data
included
company
updated
corporate
presentation
accessed
via
presentations
events
section
ovid
website
soticlestat
soticlestat
potent
highly
selective
inhibitor
enzyme
cholesterol
potential
reduce
seizure
susceptibility
improve
seizure
control
predominantly
expressed
brain
converts
cholesterol
adjust
homeostatic
balance
brain
cholesterol
positive
allosteric
modulator
nmda
receptor
modulates
glutamatergic
signaling
associated
epilepsy
glutamate
one
main
neurotransmitters
brain
shown
play
role
initiation
spread
seizure
activity
recent
literature
indicates
involved
glutamatergic
pathway
modulation
nmda
channel
increased
expression
disrupt
reuptake
glutamate
astrocytes
resulting
epileptogenesis
neurotoxicity
inhibition
soticlestat
reduces
neuronal
levels
may
improve
excitatory
inhibitory
balance
nmda
channel
activity
ovid
takeda
recently
announced
positive
topline
results
randomized
phase
elektra
study
soticlestat
children
dravet
syndrome
ds
syndrome
lgs
takeda
ovid
sharing
development
commercialization
costs
soticlestat
basis
successful
companies
share
profits
basis
takeda
responsible
commercialization
japan
option
responsible
commercialization
countries
asia
selected
countries
ovid
responsible
clinical
development
activities
commercialization
soticlestat
united
states
europe
canada
israel
terms
agreement
takeda
received
equity
ovid
may
eligible
receive
certain
milestone
payments
based
advancement
soticlestat
deficiency
disorder
syndrome
deficiency
disorder
cdd
duplication
syndrome
rare
severe
developmental
epileptic
encephalopathies
dees
caused
genetic
mutations
gene
x
chromosome
partial
duplication
chromosome
respectively
mutations
thought
among
effects
result
excess
transmission
glutamate
excitatory
neurotransmitter
turn
leads
epilepsy
characteristic
neurobehavioral
symptoms
cdd
syndrome
despite
availability
medicines
epilepsy
generally
approved
therapies
cdd
syndrome
developmental
epileptic
encephalopathies
dees
international
league
epilepsy
ilae
defines
epileptic
encephalopathy
condition
epileptiform
eeg
abnormalities
believed
contribute
progressive
disturbance
cerebral
function
epilepsies
cause
significant
morbidities
patients
beyond
might
expected
known
underlying
pathology
alone
worsen
time
developmental
epileptic
encephalopathies
typically
present
early
life
often
associated
severe
cognitive
developmental
impairment
addition
frequent
seizures
throughout
person
lifetime
disorders
vary
age
onset
developmental
outcomes
etiologies
neuropsychological
deficits
electroencephalographic
eeg
patterns
seizure
types
prognosis
despite
availability
medicines
epilepsy
approved
therapies
dees
several
types
approved
therapies
novel
therapies
needed
current
therapies
fail
alter
course
disease
address
many
patients
suffer
resistant
seizures
despite
treatment
multiple
drugs
aeds
ovid
therapeutics
ovid
therapeutics
new
biopharmaceutical
company
using
approach
develop
medicines
transform
lives
patients
rare
neurological
disorders
ovid
broad
pipeline
potential
medicines
company
advanced
investigational
medicine
gaboxadol
currently
clinical
development
treatment
angelman
syndrome
fragile
x
syndrome
ovid
also
developing
soticlestat
collaboration
takeda
pharmaceutical
company
limited
potential
treatment
rare
developmental
epileptic
encephalopathies
dees
information
ovid
please
visit
statements
press
release
includes
certain
disclosures
contain
statements
including
without
limitation
statements
regarding
potential
benefits
clinical
regulatory
development
commercialization
soticlestat
potential
value
benefits
collaboration
takeda
likelihood
data
support
future
development
association
data
treatment
outcomes
identify
statements
contain
words
appears
believes
statements
based
ovid
current
expectations
assumptions
statements
relate
future
subject
inherent
uncertainties
risks
changes
circumstances
may
differ
materially
contemplated
statements
neither
statements
historical
fact
guarantees
assurances
future
performance
important
factors
could
cause
actual
results
differ
materially
statements
include
uncertainties
development
regulatory
approval
processes
fact
initial
data
clinical
trials
may
indicative
guarantees
final
results
clinical
trials
subject
risk
one
clinical
outcomes
may
materially
change
patient
enrollment
continues
patient
data
become
available
additional
risks
could
cause
actual
results
differ
materially
statements
set
forth
ovid
filings
securities
exchange
commission
caption
risk
risks
may
amplified
pandemic
potential
impact
ovid
business
global
economy
ovid
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
contacts
investors
media
ovid
therapeutics
investor
relations
public
relations
irpr
investors
steve
klass
burns
mcclellan
sklass
media
dan
budwick
dan
